自身免疫性胃炎 中国就医指南

Autoimmune gastritis (AIG) is a chronic, immune-mediated inflammatory disorder characterized by the progressive destruction of gastric parietal cells and intrinsic factor–producing chief cells in the gastric corpus and fundus. This leads to achlorhydria (absent or severely reduced gastric acid secretion), hypergastrinemia, and impaired vitamin B12 absorption—ultimately resulting in pernicious anemia if untreated. Pathogenesis centers on loss of immune tolerance: autoreactive CD4+ T lymphocytes infiltrate the gastric mucosa, triggering antibody production against parietal cell H+/K+ ATPase (the proton pump) and intrinsic factor. These autoantibodies—particularly anti–H+/K+ ATPase antibodies—are highly specific (>90%) for AIG and serve as key diagnostic biomarkers. Complement activation and cytokine-driven mucosal atrophy further perpetuate glandular loss, metaplasia (often intestinal), and increased risk of gastric neuroendocrine tumors (type I carcinoids) and gastric adenocarcinoma. Epidemiologically, AIG affects approximately 0.5–2% of the general population, with prevalence rising sharply with age—reaching 2–5% in adults over 60 years. It is significantly more common in women (F:M ≈ 3:1) and strongly associated with other autoimmune conditions, including Hashimoto’s thyroiditis (30–50% co-occurrence), type 1 diabetes mellitus (5–10%), vitiligo, and Addison’s disease. Genetic susceptibility involves HLA-DRB1*03:01 and HLA-DQB1*02:01 alleles. Environmental triggers remain poorly defined but may include molecular mimicry following viral or bacterial infections (e.g., Helicobacter pylori—though AIG is typically H. pylori-negative, prior infection may modulate immune responses). Risk factors include female sex, age >50 years, personal or family history of autoimmunity, and certain genetic polymorphisms in immune-regulatory genes (e.g., CTLA-4, PTPN22). Clinically, AIG is often insidious and asymptomatic in early stages; when symptoms emerge, they are frequently nonspecific—fatigue, pallor, dyspnea on exertion (due to B12-deficiency anemia), glossitis, paresthesias, or mild epigastric discomfort. Importantly, patients rarely report classic dyspepsia or reflux, distinguishing AIG from functional dyspepsia or H. pylori gastritis. Quality of life impact is substantial but underrecognized: chronic fatigue and cognitive fog from B12 deficiency impair work performance and daily functioning; neurological complications (subacute combined degeneration) may become irreversible without timely intervention; psychological burden includes anxiety about cancer risk and lifelong dependency on injectable or high-dose oral B12 replacement. Long-term surveillance via endoscopy with targeted biopsies is recommended every 3–5 years in patients with extensive atrophy or intestinal metaplasia to detect dysplasia or early neoplasia. Patient education, multidisciplinary care (gastroenterology, hematology, endocrinology), and proactive monitoring are essential to mitigate morbidity and preserve quality of life.

# 自身免疫性胃炎治疗方案与费用明细（消化内科）

一、非手术/保守治疗方案

适用人群：早期确诊、无严重萎缩/肠化、维生素B₁₂轻度缺乏者。

• •基础药物治疗：

• •检查/检验费：胃镜+活检（含病理）、血清抗壁细胞抗体（APCA）、内因子抗体（IFA）、血清B₁₂、铁蛋白、胃泌素-17：1,200–1,800元/次

二、手术/介入方案

本病属慢性自身免疫性疾病，无根治性手术指征；胃切除术等外科干预为绝对禁忌，不适用于自身免疫性胃炎本身。仅当合并高风险病变（如重度异型增生或早期胃癌）时，按胃癌诊疗规范行内镜下黏膜剥离术（ESD）：

• •ESD术前检查（增强CT、超声胃镜、心肺评估）：3,200–4,500元
• •ESD手术及住院（含麻醉、病理、护理）：28,000–42,000元（医保报销后自付约8,000–15,000元）

三、特殊复杂情况处理

• •合并恶性贫血需长期B₁₂替代：肌注方案年均2,000–3,500元；静脉B₁₂（难吸收者）：6,000–9,000元/年
• •重度胃体萎缩伴低胃酸/细菌过度生长：加用短期抗生素（利福昔明）+ 微生态调节：1,500–3,000元/疗程

四、方案快速选择指南

• •预算有限/初诊患者：首选保守治疗+年度监测，年总支出≤4,000元
• •B₁₂严重缺乏/神经系统症状者：强化B₁₂替代+每半年胃镜随访，年支出6,000–12,000元
• •发现癌前病变者：转至消化内镜中心行ESD，单次总费用约3.5万–5万元（含医保）